Skip to content

Nuvalent, Inc. NUVL Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Pfizer logo
PfizerPFE
Summit Therapeutics logo
Summit TherapeuticsSMMT
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Incyte logo
IncyteINCY
ALN
Alnylam PharmaceuticalsALNY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s deferred tax assets and other non-current assets?
Nuvalent, Inc. (NUVL) reported deferred tax assets and other non-current assets of $23.21M in Q1 2026.
How has Nuvalent, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Nuvalent, Inc.'s deferred tax assets and other non-current assets increased by 20.6% year-over-year, from $19.25M to $23.21M.
What is the long-term trend for Nuvalent, Inc.'s deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s deferred tax assets and other non-current assets has grown at a 58.7% compound annual growth rate (CAGR), from $3.2M to $20.28M.